Prostate Cancer Clinical Guidelines Panel Summary Report on the Management of Clinically Localized Prostate Cancer

Middleton, Richard G.; Thompson, Ian M.; Austenfeld, Mark S.; Cooner, William H.; Correa, Roy J.; Gibbons, Robert P.; Miller, Harry C.; Öesterling, Joseph E.; Resnick, Martin I.; Smalley, Stephen R.; Wasson, John H.

doi:10.1097/00005392-199512000-00051

Cited by 54 publications

(63 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Scientific evidence supporting effective preventive behaviors for most cancers is weak (Taubes, 1995), and the relative value of some screening tests is uncertain (American Urological Association [AUA], 2000; National Cancer Institute [NCI], 2003;Smith, Cokkinides, & Eyre, 2005;USPSTF, 2002bUSPSTF, , 2002c. Many treatment options are available for several cancers with little agreement about which are best at various stages of disease (Middleton et al, 1995;National Comprehensive Cancer Network [NCCN], 2004).…”

mentioning

confidence: 99%

Cancer News Coverage and Information Seeking

Niederdeppe

Frosch

Hornik

2008

Journal of Health Communication

View full text Add to dashboard Cite

The shift toward viewing patients as active consumers of health information raises questions about whether individuals respond to health news by seeking additional information. This study examines the relationship between cancer news coverage and information seeking using a national survey of adults aged 18 years and older. A Lexis-Nexis database search term was used to identify Associated Press (AP) news articles about cancer released between October 21, 2002, and April 13, 2003. We merged these data to the Health Information National Trends Survey (HINTS), a telephone survey of 6,369 adults, by date of interview. Logistic regression models assessed the relationship between cancer news coverage and information seeking. Overall, we observed a marginally significant positive relationship between cancer news coverage and information seeking (p < 0.07). Interaction terms revealed that the relationship was apparent only among respondents who paid close attention to health news (p < 0.01) and among those with a family history of cancer (p < 0.05). Results suggest that a notable segment of the population actively responds to periods of elevated cancer news coverage by seeking additional information, but they raise concerns about the potential for widened gaps in cancer knowledge and behavior between large segments of the population in the future.The growing emphasis in clinical medicine on patients participating more actively in making health care decisions, combined with rapid growth in the availability of health information, creates potential for widespread use of publicly available information in medical decisions (Frosch & Kaplan, 1999). In light of these systemic changes, it is vitally important to understand how health consumers navigate the health information environment. Information seeking is increasingly viewed as an important mediator between health information in the media and subsequent health knowledge and behaviors (Griffin, Dunwoody, & Neuwirth, 1999;Johnson, 1997;Niederdeppe et al., 2007). Optimistic views suggest that many search for additional health information when exposed to health news (Campion, 2004;Nelson et al., 2004), but the extent to which this occurs remains largely unknown. This article examines the relationship between cancer news coverage and information seeking using data from a national survey. News Coverage and Health BehaviorHealth news coverage has contributed to notable changes in preventive behavior. Lagged timetrend analyses link news coverage to decreases in the administration of aspirin to children and (Soumerai, Ross-Degnan, & Kahn, 2002), reductions in youth marijuana use (Stryker, 2003), increased smoking cessation (Pierce & Gilpin, 2001), decreases in youth cocaine use (Fan & Holway, 1994), reductions in HIV infection in gay men (Fan, 2002), reduced youth binge drinking (Yanovitzky & Stryker, 2001), increased mammography use (Yanovitzky & Blitz, 2000), and lowered levels of drunk driving (Yanovitzky & Bennett, 1999). In most of these cases, changes in behavior tr...

show abstract

mentioning

confidence: 99%

Cancer News Coverage and Information Seeking

Niederdeppe

Frosch

Hornik

2008

Journal of Health Communication

View full text Add to dashboard Cite

show abstract

“…When this information is evaluated, platelet may be associated with total PSA values that can be used for diagnosing prostate cancer. Many clinical studies report that advanced age is a significant risk factor for prostate cancer [20,21]. When this information is evaluated together, advanced age is an important factor related to the total PSA values.…”

Section: Discussionmentioning

confidence: 99%

Estimation of total prostate specific antigen values through artificial intelligence modelling

Yaşar¹,

Beytur²,

Çolak³

2018

Med-Science

View full text Add to dashboard Cite

It has been indicated that total prostate specific antigen (PSA) screening, one of the serum markers used for the diagnosis of prostate cancer, has been clinically beneficial. In this research, it was aimed to estimate the total PSA values by Multilayer Perceptron (MLP) artificial neural network (ANN) model. Data on total PSA values in this study (n = 1422) were randomly selected using the structured query language (SQL) from the database of patients records of Urology Department of Medical School at Inonu University. Total PSA values as a target/dependent variable, and age (year), blood group (A/B/0/AB), Exitus (EX) status (alive/death), Lymphocyte (LY) (%), Hemoglobin (HGB) (g / dL), Neutrophil (NE) (%), Albumin (g / dL), Calcium (mg / dL), Mean Corpuscular Hemoglobin (MCH), Leukocyte count (WBC) (103 / ml), Platelet (PLT) (103/ ml) as predictor variables were evaluated in the analyses. Outlier/extreme observations were analysed, and quantitative variables were rescaled by the transformation of Z-score or Box-Cox, and the MLP ANN model was constructed to estimate the total PSA values after variable selection method was used. Estimation performance of the model was examined by the values of mean absolute error, standard deviation and correlation coefficient. The MLP ANN model was created using a total of 1422 data sets as 993 of which were in training and 429 in the testing. Values of the mean absolute error, standard deviation, and correlation coefficient were calculated for training data set as; 0.744, 0.895 and 0.452; for the test data set as; 0.773, 0.935 and 0.355. The estimated accuracy of the generated model is predicted as 20.3%. In the MLP ANN model, the importance levels of the variables were obtained as 0.33 for HGB, 0.22 for NE, 0.16 for Calcium, 0.13 for PLT, 0.10 for age and 0.06 for EX. The MLP ANN model was established for the estimation of the total PSA values based on the selected variables, and calculated the importance levels of the related variables. Better prediction results in the estimation of total PSA values can be provided by using different additional variables, various resampling methods and alternative models.

show abstract

“…The biases that were obvious in the literature such as varying proportions of grade 3 tumors, stage migration and a mixture of prevalent and incident cases were accounted for in the compilation by Adolfsson et al 4 Also, the number of studies than can be used for compiling data for deferred treatment of localized prostate cancer are limited which compromises the precision of the data. 4,5 Therefore, the outcome data in these studies can probably not be used for direct comparisons between treatments.…”

Section: Compilations Of Data From Single Treatment Seriesmentioning

confidence: 99%

Conservative management of clinically localized prostate cancer

Adolfsson

1997

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The purpose of this paper is to review and summarize the current knowledge on conservative management of localized prostate cancer. Deferring treatment for low-grade, clinically localized prostate cancer is an acceptable treatment option for patients with a life expectancy of 10±15 y or less. The outcome of available studies on deferred treatment in selected series cannot be compared with the outcome in register studies where the patients have been managed with noncurative intent, nor can it be directly compared with the outcome of selected series on other treatments. The outcome of different treatments for localized prostate cancer can only be compared in randomized studies.

show abstract

Prostate Cancer Clinical Guidelines Panel Summary Report on the Management of Clinically Localized Prostate Cancer

Cited by 54 publications

References 0 publications

Cancer News Coverage and Information Seeking

Cancer News Coverage and Information Seeking

Estimation of total prostate specific antigen values through artificial intelligence modelling

Conservative management of clinically localized prostate cancer

Contact Info

Product

Resources

About